Milestone Net Debt from 2010 to 2026

MIST Stock  USD 1.82  0.02  1.09%   
Milestone Pharmaceuticals Net Debt yearly trend continues to be comparatively stable with very little volatility. Net Debt is likely to outpace its year average in 2026. Net Debt is the total debt of Milestone Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals
 
Net Debt  
First Reported
2018-03-31
Previous Quarter
13.9 M
Current Value
10.5 M
Quarterly Volatility
58.5 M
 
Covid
 
Interest Hikes
Check Milestone Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Milestone Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 1.1 M or Interest Income of 5 M, as well as many indicators such as Price To Sales Ratio of 32.97, Dividend Yield of 0.0 or PTB Ratio of 10.55. Milestone financial statements analysis is a perfect complement when working with Milestone Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Milestone Stock
Check out the analysis of Milestone Pharmaceuticals Correlation against competitors.
For more information on how to buy Milestone Stock please use our How to Invest in Milestone Pharmaceuticals guide.
The evolution of Net Debt for Milestone Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Milestone Pharmaceuticals compares to historical norms and industry peers.

Latest Milestone Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of Milestone Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Milestone Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Milestone Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Debt10 Years Trend
Pretty Stable
   Net Debt   
       Timeline  

Milestone Net Debt Regression Statistics

Arithmetic Mean(20,308,460)
Coefficient Of Variation(240.84)
Mean Deviation36,332,842
Median(10,880,000)
Standard Deviation48,911,051
Sample Variance2392.3T
Range157.3M
R-Value0.17
Mean Square Error2481.1T
R-Squared0.03
Significance0.52
Slope1,612,367
Total Sum of Squares38276.7T

Milestone Net Debt History

202635.6 M
202533.9 M
202429.5 M
202338 M
2022-5.1 M
2021-113.4 M
2020-71.4 M

Other Fundumenentals of Milestone Pharmaceuticals

Milestone Pharmaceuticals Net Debt component correlations

0.860.88-0.47-0.580.960.290.590.58-0.460.891.01.00.780.490.78
0.860.94-0.49-0.460.830.150.660.49-0.820.940.860.860.760.370.75
0.880.94-0.23-0.720.880.450.750.72-0.741.00.880.870.920.640.92
-0.47-0.49-0.23-0.36-0.40.540.090.320.19-0.23-0.48-0.50.050.490.06
-0.58-0.46-0.72-0.36-0.64-0.82-0.59-0.960.32-0.72-0.56-0.53-0.91-0.94-0.92
0.960.830.88-0.4-0.640.430.580.63-0.450.880.960.950.80.540.8
0.290.150.450.54-0.820.430.550.71-0.010.450.280.240.680.810.68
0.590.660.750.09-0.590.580.550.47-0.570.750.580.560.740.710.74
0.580.490.720.32-0.960.630.710.47-0.390.720.560.540.890.890.9
-0.46-0.82-0.740.190.32-0.45-0.01-0.57-0.39-0.74-0.46-0.46-0.56-0.3-0.56
0.890.941.0-0.23-0.720.880.450.750.72-0.740.880.870.920.640.92
1.00.860.88-0.48-0.560.960.280.580.56-0.460.881.00.770.480.77
1.00.860.87-0.5-0.530.950.240.560.54-0.460.871.00.740.440.74
0.780.760.920.05-0.910.80.680.740.89-0.560.920.770.740.841.0
0.490.370.640.49-0.940.540.810.710.89-0.30.640.480.440.840.86
0.780.750.920.06-0.920.80.680.740.9-0.560.920.770.741.00.86
Click cells to compare fundamentals

About Milestone Pharmaceuticals Financial Statements

Milestone Pharmaceuticals shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Milestone Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Milestone Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Milestone Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Debt33.9 M35.6 M
Net Debt To EBITDA(0.90)(0.85)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Milestone Stock Analysis

When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.